Results of surgical treatment of resectable liver metastases in colorectal cancer at the University Clinical Centre Maribor
Rezultati kirurškega zdravljenja resektabilnih jetrnih metastaz pri raku debelega črevesa in danke v UKC Maribor
Keywords:
colorectal neoplasms, liver, metastases, colon, cancer, surgical, survivalAbstract
Background: Only surgical treatment in patients with liver metastases (LM) in colorectal cancer (CC), which is nowadays often combined with other forms of treatment, offers the possibility of long-term survival or even hope of a cure. The aim of this study is to present the possibilities of multimodal treatment and to assess the results of such treatment of LM in CC in our patients.
Methods: In the period from 1 July 1997 to 31 December 2011, a total of 377 liver surgeries were performed in 281 patients with metastases of CC (107 men, 103 women; mean age 63.3 years; span of 27 to 85 years).
Results: Of 377 surgeries for LM of CC, liver resection was performed 324 times, and in 28 of those patients in combination with RFA. 235 (79.4%) were R0 resections, 54 (18.2%) were R1 and 7 (2.4% were R2 resections. A total of 53 procedures were RFA of LM. In 113 patients, LM were diagnosed synchronously with CC, and 168 men had metachronous LM. Unilobar metastases were found in 145 patients, and 136 had bilobar metastases. On average, there were 2.9 liver metastases with an average size of 4.3 cm. In 46 patients, the disease was present also outside the liver. Prior to liver surgery, 131 patients underwent neoadjuvant chemotherapy. In 16 cases, portal embolisation was performed to increase the residual liver volume, and ligature of the right branch of the vena porta was performed 10 times. Simultaneous liver resection was performed in 41 patients. At the first surgery, liver resection was performed in 252 patients. Liver resection alone was performed in 239 patients, whereas in 23 patients, it was combined with radiofrequency ablation of LM (RFA). Of 239 LM resections without additional RFA, 198 (83%) were R0 resections, 36 (15%) were R1 and 5 (2%) were R2 resections. In 29 patients, only RFA of LM was performed (open RFA 20 times, percutaneous RFA 9 times). Surgery for disease recurrences was performed on 73 patients, who underwent 96 procedures (1 to 6 per patient). Considering all surgeries (377), the total post-operative incidence was 25.5%, and 30-day morbidity was 1.9%. The expected 5-year survival in patients with R0 resection of LM and no disease outside the liver was 38.3% (median survival: 43 months
Conclusions: Liver resections are safe (morbidity: 25.5%; 30-day morbidity: 1.9% in R0 resections). Considering the expected long-term survival (5-year of 38.8%, median of 43 months), they currently represent the most effective method for the treatment patients with metastases of CC. The focus is on the importance of a multidisciplinary approach and multi modal treatment of patients with metastases of CC.
Methods: In the period from 1 July 1997 to 31 December 2011, a total of 377 liver surgeries were performed in 281 patients with metastases of CC (107 men, 103 women; mean age 63.3 years; span of 27 to 85 years).
Results: Of 377 surgeries for LM of CC, liver resection was performed 324 times, and in 28 of those patients in combination with RFA. 235 (79.4%) were R0 resections, 54 (18.2%) were R1 and 7 (2.4% were R2 resections. A total of 53 procedures were RFA of LM. In 113 patients, LM were diagnosed synchronously with CC, and 168 men had metachronous LM. Unilobar metastases were found in 145 patients, and 136 had bilobar metastases. On average, there were 2.9 liver metastases with an average size of 4.3 cm. In 46 patients, the disease was present also outside the liver. Prior to liver surgery, 131 patients underwent neoadjuvant chemotherapy. In 16 cases, portal embolisation was performed to increase the residual liver volume, and ligature of the right branch of the vena porta was performed 10 times. Simultaneous liver resection was performed in 41 patients. At the first surgery, liver resection was performed in 252 patients. Liver resection alone was performed in 239 patients, whereas in 23 patients, it was combined with radiofrequency ablation of LM (RFA). Of 239 LM resections without additional RFA, 198 (83%) were R0 resections, 36 (15%) were R1 and 5 (2%) were R2 resections. In 29 patients, only RFA of LM was performed (open RFA 20 times, percutaneous RFA 9 times). Surgery for disease recurrences was performed on 73 patients, who underwent 96 procedures (1 to 6 per patient). Considering all surgeries (377), the total post-operative incidence was 25.5%, and 30-day morbidity was 1.9%. The expected 5-year survival in patients with R0 resection of LM and no disease outside the liver was 38.3% (median survival: 43 months
Conclusions: Liver resections are safe (morbidity: 25.5%; 30-day morbidity: 1.9% in R0 resections). Considering the expected long-term survival (5-year of 38.8%, median of 43 months), they currently represent the most effective method for the treatment patients with metastases of CC. The focus is on the importance of a multidisciplinary approach and multi modal treatment of patients with metastases of CC.
Povzetek
Izhodišča: Pri bolnikih z jetrnimi metastazami (JM) pri kolorektalnem raku (KRR) le kirurško zdravljenje, sedaj pogosto kombinirano z drugimi načini zdravljenja, nudi možnost dolgotrajnejšega preživetja ali pa celo upanje na ozdravitev. Namen raziskave je prikaz možnosti multimodalnega načina zdravljenja in ocenitev rezultatov takšnega zdravljenja JM pri KRR pri naših bolnikih. Metode: V obdobju od 1. julija 1997 do 31. decembra 2011 je bilo opravljenih 377 jetrnih operacij pri 281 bolnikih z metastazami KRR (178 moški, 103 ženske; povprečna starost 63,3 leta; razpon 27 do 85 let). Rezultati: Od skupno 377 operacij zaradi JM KRR je bila 324-krat opravljena resekcija jeter, od tega pri 28 bolnikih kombinirana z RFA. 235 (79,4 %) je bilo R0 resekcij, 54 (18,2 %) je bilo R1 in 7 (2,4 %) R2 resekcij. Skupno 53 posegi so bile RFA JM. Pri 113 bolnikih so bile JM ugotovljene sinhrono ob ugotovitvi KRR, pri 168 pa je šlo za metahrone JM. 145 bolnikov je imelo unilobarne, 136 pa bilobarne metastaze. Povprečno je bilo 2,9 jetrnih metastaz, povprečna velikost metastaz pa je bila 4,3 cm. Pri 46 bolnikih je bilo obolenje prisotno tudi zunaj jeter. 131 bolnikov je pred jetrno operacijo prejemalo neoadjuvantno kemoterapijo. 16-krat je bila za povečanje preostanka jeter opravljena portalna embolizacija, 10-krat pa ligatura desne veje vene porte. Simultana resekcija jeter je bila narejena pri 41 bolnikih. Pri prvi operaciji je bila opravljena resekcija jeter pri 252 bolnikih. Pri 239 bolnikih je bila narejena samo resekcija jeter, pri 23 bolnikih pa je bila resekcija kombinirana še z radiofrekventno ablacijo JM (RFA). Od 239 resekcij JM brez dodatne RFA je bilo 198 (83 %) resekcij R0, 36 (15 %) R1, 5 (2 %) pa R2 resekcij. Pri 29 bolnikih je bila narejena samo RFA JM (20-krat odprta RFA, 9-krat perkutana RFA). Zaradi ponovitve obolenja smo operirali 73 bolnikov, pri katerih smo opravili 96 posegov (1 do 6 na bolnika). Upoštevajoč vse opravljene operacije (377) je bila skupna pooperacijska obolevnost 25,5 %, 30-dnevna umrljivost pa je bila 1,9 %. Pričakovano 5-letno preživetje pri bolnikih z R0 resekcijo JM in brez zunaj jetrnega obolenja je bilo 38,3 % (mediano preživetje: 43 mesecev). Zaključki: Resekcije jeter so varne (morbiditeta: 25,5 %; 30 mortaliteta: 1,9 pri R0 resekcijah), glede na pričakovano dolgoročno preživetje (5-letno 38,3 %, mediana 43 mesecev) pa trenutno predstavljajo najučinkovitejši način zdravljenja bolnikov z metastazami KRR. Poudarjen je pomen multidisciplinarnega pristopa in multimodalnega zdravljenja bolnikov z metastazami KRR ; slv - slovenski
Downloads
Published
2013-06-15
Issue
Section
Review Article
License
The journal is published under the terms of the Creative Commons Attribution License CC-BY 4.0. The authors retain the copyright to their work without any restrictions whatsoever.
This journal is an open-access journal, meaning that all of its contents are freely accessible without any charge to the user or their institution. In accordance with the Budapest Open Access Initiative (BOAI) definition of open access, users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking for prior permission from the publisher or the author, provided the authors and the journal are appropriately credited.
How to Cite
Results of surgical treatment of resectable liver metastases in colorectal cancer at the University Clinical Centre Maribor. (2013). Onkologija, 17(1), 44-51. https://www.revijaonkologija.si/Onkologija/article/view/177
